These are the trials that are currently open in the Early Phase Unit (Last updated 13 September 2018).
| Trial Short Name | Molecular Target(s) | Patient Population | Lead Investigator(s) in Cambridge |
| AZD1390 | ATM with RT | Glioblastoma | S Jeffries / R Baird |
| AZD6738 combo with olaparib |
ATR/PARP | Gastric cancer (low ATM expression) & BRCA mutation/HRD high breast cancer |
D Jodrell |
| AZD8186 | PIK3CB | Prostate, TNBC, NSCLC, with pre-screening for PTEN deficiency | R Baird |
| CALIBRATE | cfDNA evaluation | Patients on early phase clinical trials | R Baird / S Pacey |
| CamBMT1 phase II | EGFR/HER2 | Operable brain metastasis (breast/lung) | R Baird |
| CAM-PLEX | CXCR4 | Metastatic pancreatic cancer with biopsiable disease | D Jodrell / B Basu |
| CURIS | PD-1/PD-L1/VISTA | Any tumour site with FDA approved immunotherapy option | S Pacey |
| G1T38 | CDK4/6 | ER-positive breast cancer, CDK4/6 inhibitor plus fulvestrant | R Baird |
| iBET | Bromodomain | Haematologic malignancies | B Huntly |
| ONX-0801 | α-folate receptor | Platinum resistant ovarian cancer | B Basu |
| OUTREACH MNA-3521 |
CEBPα | Hepatocellular carcinoma | B Basu |
| PARADIGM 2 | PARP | Glioblastoma stratified by MGMT status | S Jeffries / R Baird |
| POSEIDON phase II | PI3K | HR+ metastatic breast cancer | R Baird |
| STARTRK2 | NTRK1/2/3/ROS1/ALK | Proven NTRK1/2/3, ROS1 or ALK gene rearrangements | S Pacey |
| VAPER | hTERT | Advanced solid tumours | R Baird |